Pharmacoeconomic Analysis of Anidulafungin (Eraxis®) Use in the Treatment of Invasive Candidiasis

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(3):235-244

Type
Journal article

Abstract

Invasive candidiasis is a common infectious complication in intensive care units and hematological malignancies chemotherapy units. This study presents data from the first-in-Russia health economics review of the anidulafungin use in the treatment of adults with candidiasis compared to standard and alternative therapies. The main study method was modeling based on a literature review of data on the use of antifungals in high-risk patients for fungal infection. Both primary and alternative scenarios as well as one-sided sensitivity analysis and likelihood analysis (Monte Carlo simulation) were used. Results from this pharmacoeconomic analysis suggest that the use of anidulafungin in the treatment of adult patients with invasive candidiasis is reasonable. The advantages of anidulafungin over other antifungals in the treatment of invasive candidiasis were as follows: the lowest direct costs, the highest efficacy outcomes, and the most favorable cost-effectiveness.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared